← Back to home

Epstein-Barr virus+ associated post-transplant lymphoproliferative disease (EBV+ PTLD)

Clinical trials for Epstein-Barr virus+ associated post-transplant lymphoproliferative disease (EBV+ PTLD) explained in plain language.

Never miss a new study

Get alerted when new Epstein-Barr virus+ associated post-transplant lymphoproliferative disease (EBV+ PTLD) trials appear

Sign up with your email to follow new studies for Epstein-Barr virus+ associated post-transplant lymphoproliferative disease (EBV+ PTLD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Trials to join now! 1

Donor immune cells take on Virus-Linked cancer after transplant

Disease control Recruiting now

This phase 3 trial tests tabelecleucel, a cell therapy made from donor immune cells, in 115 organ or stem cell transplant patients who developed a rare cancer (EBV+ PTLD) after standard treatment failed. The goal is to see if it can shrink tumors and improve outcomes. Participant…

Matched conditions: EPSTEIN-BARR VIRUS+ ASSOCIATED POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE (EBV+ PTLD)

Phase 3 • Sponsor: Pierre Fabre Medicament • Aim: Disease control

Last updated Sep 04, 2026 00:00 UTC

Epstein-Barr virus+ associated post-transplant lymphoproliferative disease (EBV+ PTLD)

Get alerted when new Epstein-Barr virus+ associated post-transplant lymphoproliferative disease (EBV+ PTLD) trials appear

Donor immune cells take on Virus-Linked cancer after transplant